Richard C. Young & CO. LTD. Sells 3,305 Shares of Sanofi (NASDAQ:SNY)

Richard C. Young & CO. LTD. reduced its holdings in shares of Sanofi (NASDAQ:SNY) by 9.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 31,389 shares of the company’s stock after selling 3,305 shares during the quarter. Richard C. Young & CO. LTD.’s holdings in Sanofi were worth $1,514,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in SNY. Apollon Wealth Management LLC raised its holdings in Sanofi by 8.8% in the 4th quarter. Apollon Wealth Management LLC now owns 17,865 shares of the company’s stock valued at $862,000 after acquiring an additional 1,441 shares during the period. Mezzasalma Advisors LLC increased its stake in shares of Sanofi by 24.0% during the fourth quarter. Mezzasalma Advisors LLC now owns 12,686 shares of the company’s stock worth $612,000 after purchasing an additional 2,452 shares during the period. Strategic Financial Concepts LLC acquired a new stake in Sanofi during the 4th quarter worth approximately $667,000. Leo Wealth LLC boosted its stake in Sanofi by 5.9% in the 4th quarter. Leo Wealth LLC now owns 26,669 shares of the company’s stock valued at $1,286,000 after purchasing an additional 1,487 shares during the period. Finally, Yousif Capital Management LLC grew its holdings in Sanofi by 53.2% in the 4th quarter. Yousif Capital Management LLC now owns 59,611 shares of the company’s stock valued at $2,875,000 after buying an additional 20,690 shares in the last quarter. 14.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Trading Up 0.9 %

Shares of Sanofi stock opened at $53.35 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The company has a market capitalization of $135.39 billion, a price-to-earnings ratio of 21.43, a PEG ratio of 0.99 and a beta of 0.57. The firm’s 50-day moving average price is $49.72 and its two-hundred day moving average price is $52.38.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. On average, analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $60.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.